 CAMBRIDGE, Mass., March 05, 2021 GLOBE NEWSWIRE -- Sigilon Therapeutics, Inc. NASDAQ:SGTX, a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living TherapeuticsTM platform, today announced that the United States Food and Drug Administration FDA has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening lysosomal disease. 